Published in Breast Cancer Res Treat on January 12, 2016
Molecular portraits of human breast tumours. Nature (2000) 94.14
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Caspases: the executioners of apoptosis. Biochem J (1997) 11.99
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
The role of epithelial-mesenchymal transition in cancer pathology. Pathology (2007) 5.16
Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer (2002) 4.76
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Molecular stratification of triple-negative breast cancers. Oncologist (2011) 2.81
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res (1999) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol (1997) 2.07
Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem (2000) 1.68
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis (2010) 1.64
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res (2002) 1.58
E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Mol Cell (2014) 1.55
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat (2008) 1.44
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat (2009) 1.27
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest (2015) 1.24
Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol (2001) 1.21
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol (2006) 1.20
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am J Clin Pathol (2003) 1.00
Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev (2013) 0.96
P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol (2010) 0.95
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res (2011) 0.91
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer (2013) 0.90
Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol (2014) 0.82
AXL mediates TRAIL resistance in esophageal adenocarcinoma. Neoplasia (2013) 0.80
P-cadherin and vimentin are useful basal markers in breast cancers. Hum Pathol (2013) 0.79